Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980807 · ClinicalTrials.gov registry record
Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
A clinical trial of Charcot Marie Tooth Disease, sponsored by NMD Pharma A/S.
- Completed
- Registry status
- 30
- Enrollment target
- 2
- Study locations
NCT04980807: Completed study of Charcot Marie Tooth Disease, sponsored by NMD Pharma A/S.
NCT04980807 is a study of Charcot Marie Tooth Disease that has completed, run by NMD Pharma A/S. The registered enrollment target is 30 participants, below the 2,361-participant average among 7 other Charcot Marie Tooth Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04980807, a study of Charcot Marie Tooth Disease, has completed, sponsored by NMD Pharma A/S.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary aim of this study is to discover whether patients with CMT type 1 and 2 have neuromuscular junction transmission deficits. The secondary aim is to collect information of different clinical and electrophysiological test procedures to perform possible future clinical trials in CMT patients.
Primary Outcome
Percentage decrement of CMAP for the trapezius
Conditions Studied
Study Locations (2)
Ohio
- Ohio State University - Columbus
Jutland
- Aarhus University Hospital - Aarhus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-07 |
| Est. Completion | 2022-03-03 |
What the finished NCT04980807 record still lists
NCT04980807 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,361-participant average among 7 other Charcot Marie Tooth Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Charcot Marie Tooth Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04980807 reports a single indexed study location in Ohio, Jutland.
Frequently Asked Questions
What is clinical trial NCT04980807 about?
NCT04980807 is a clinical study titled "Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls". The primary aim of this study is to discover whether patients with CMT type 1 and 2 have neuromuscular junction transmission deficits. The secondary aim is to collect information of different clinical and electrophysiological test procedures to perform possible future clinical trials in CMT patient...
What is the current status of trial NCT04980807?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2021-04-07. Estimated completion is 2022-03-03.
What conditions does trial NCT04980807 study?
This clinical trial studies the following conditions: Charcot Marie Tooth Disease.
Who is sponsoring clinical trial NCT04980807?
This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04980807 being conducted?
This trial has 2 study locations across Ohio, Jutland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Charcot Marie Tooth Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
RECRUITING
-
Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking
RECRUITING
-
Natural History Study for Charcot Marie Tooth Disease
RECRUITING
-
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
ACTIVE NOT RECRUITING · Phase 3
-
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)
COMPLETED
-
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI